MISSISSAUGA, ON, May 3, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2024 after the market close on Thursday, May 9, 2024. The Company will also hold a conference call on Friday, May 10, 2024 at 8:30 ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | May 10, 2024 |
TIME: | 8:30AM |
DIAL-IN NUMBER: | 416-764-8650 or 888-664-6383 |
REPLAY: | 416-764-8677 or 888-390-0541 Code:196164# |
Expires: May 17, 2024 | |
WEBCAST: |
Cipher Pharmaceuticals (TSX:CPH) (OTCQX:CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$13.98 |
| Daily Change: | 0.15 1.08 |
| Daily Volume: | 23,613 |
| Market Cap: | C$357.750M |
November 07, 2024 August 08, 2024 July 29, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
